Verification of Compendial Methods-USP <1226>-Why and How
Duration: 75 Minutes
This webinar on verification of compendial methods will give a good understanding of the revised USP Chapter <1226> and FDA requirements and also provide recommendations and tools for its effective implementation.
Why Should you Attend
Compendial methods such as USP and EP standards are validated by the organizations that have developed and published this method. The FDA requires users of such methods to demonstrate the user's competence to successfully run the method. For example, 21 CFR 211.194 (a) states: The suitability of all testing methods used shall be verified under actual conditions of use. However, the FDA does not give any further guidance on what, when and how. And the first revision of USP <1226> did not have specific recommendations. But FDA inspectors go out and write 483's and warning letters related to <1226>. Now USP did come out with a new revision using the risk based approach for the type and extend of testing.
Objectives of the Presentation
Who can Benefit
- FDA and international requirements for verification of compendial methods
- The background and scope of USP <1226>
- What's new in the second revision?
- Compendial methods not requiring verification
- USP <1226> requirements for verification and testing
- Risk based approach for type and extent of testing
- Performance characteristics for verification testing: Proven industry examples
- Acceptance criteria for testing
- How much can compendial methods be changed
- Change vs. adjustment of compendial methods
- Investigating non-performance: Root cause and corrective actions
- Documenting the verification experiments and results
- Lab Supervisors and Managers
- QA Managers and Personnel